Not sure if this has been posted before:

"CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells"

https://aacrjournals.org/cancerres/article/72...sal-Breast

Some excerpts:

Quote:

---

The CCR5 antagonists maraviroc or vicriviroc, developed to block CCR5 HIV coreceptor function, reduced in vitro invasion of basal breast cancer cells without affecting cell proliferation or viability, and maraviroc decreased pulmonary metastasis in a preclinical mouse model of breast cancer. Taken
together, our findings provide evidence for the key role of CCL5/CCR5 in the invasiveness of basal breast cancer cells and suggest that CCR5 antagonists may be used as an adjuvant therapy to reduce the risk of metastasis in
patients with the basal breast cancer subtype.

---

Quote:

---

The authors identified cancer cell extravasation as the crucial metastatic
step affected by CCL5/CCR5 inhibition. Together, thesedata support a role for CCR5 antagonists in blocking the sites instead of inhibiting their proliferation or survival after arrival. Blocking the homing of cancer cells to metastatic sites is a dntagonists may be useful as adjuvant therapy for breast basal tumors with CCR5 overexpression or other tumor types where CCR5 promotes metastasis, such as prostate cancer (50) or gastric cancer
. Our preclinical studies will expedite the path toward the clinical use of CCR5 antagonists as new treatments for dissemination of basal breast cancer.

---

So we are sitting on a potential blockbuster (Leronlimab bettaer than Maraviroc) ... and RP is now working with Maraviroc even though he has a large number of shares of CYDY.

We need to move forward ...